CARTITUDE-2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- Myeloma Service
- 21-009
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 237 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- 4 days ago
- SparkCures ID
- 1039
- NCT Identifier
- NCT04133636
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.